Entrada Therapeutics (TRDA) Earnings Analysis

Entrada Therapeutics (TRDA) has no confirmed upcoming earnings date. Last quarter (2026-05-07) it beat with EPS -0.95 USD vs -1.06 USD est (+10.4%). It has beaten estimates in 4/5 recent quarters (80%). Trailing P/E -1.54.

Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades

When does TRDA next report earnings?

No confirmed upcoming earnings date is currently scheduled for TRDA. This page updates as the calendar is published.

TRDA earnings history — beats and misses

Quarter (report date)EPS actualEPS est.SurpriseResult
2026-05-07-0.95 USD-1.06 USD+10.4%Beat
2026-02-26-0.94 USD-1.32 USD+28.8%Beat
2025-11-06-1.06 USD-1.04 USD-1.9%Miss
2025-05-08-0.42 USD-0.78 USD+46.2%Beat
2025-02-270.03 USD-0.66 USD+104.5%Beat

Beat rate: 4/5 (80%) over reported quarters with consensus data.

TRDA valuation and analyst view

Trailing P/E-1.54
Trailing EPS-3.97067 USD
Price / book0.95
Dividend yield0.00%
Market cap0.24B
Analyst consensusBuy (4 buy / 2 hold / 0 sell)
Avg price target13.5 USD

Related research pages

Frequently asked questions

When is Entrada Therapeutics (TRDA)'s next earnings date?

No confirmed upcoming earnings date is currently scheduled for TRDA. This page updates as the calendar is published.

Did TRDA beat earnings last quarter?

In its 2026-05-07 report, TRDA posted EPS of -0.95 USD versus a -1.06 USD estimate — a beat of 10.4%.

What is TRDA's earnings track record?

Over the last 5 reported quarters with consensus data, TRDA beat estimates 4 times (80%).

What is TRDA's current P/E ratio and EPS?

TRDA trades at a trailing P/E of -1.54 on trailing EPS of -3.9706689947898086 USD.

What do analysts rate TRDA?

Analyst consensus is "Buy" across 6 ratings (0 strong buy, 4 buy, 2 hold, 0 sell, 0 strong sell). Average 12-month price target: 13.5 USD.